Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · IEX Real-Time Price · USD
-0.080 (-3.49%)
At close: Jun 21, 2024, 4:00 PM
-0.010 (-0.45%)
After-hours: Jun 21, 2024, 7:59 PM EDT

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).

Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.

The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.

Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics, Inc.
Esperion Therapeutics logo
Country United States
Founded 2008
IPO Date Jun 26, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 240
CEO Sheldon L. Koenig

Contact Details

3891 Ranchero Drive, Suite 150
Ann Arbor, Michigan 48108
United States
Phone 734-887-3903

Stock Details

Ticker Symbol ESPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001434868
CUSIP Number 29664W105
ISIN Number US29664W1053
SIC Code 2834

Key Executives

Name Position
Sheldon L. Koenig President, Chief Executive Officer and Director
Benjamin O. Looker General Counsel
Dr. JoAnne Micale Foody FACC, M.D. Chief Medical Officer
Benjamin Halladay M.B.A. Chief Financial Officer
Glenn P. Brame Chief Technical Operations Officer
Tiffany Aldrich M.B.A. Associate Director of Corporate Communications
Betty Jean Swartz Chief Business Officer
Eric J. Warren R.Ph. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 18, 2024 144 Filing
Jun 18, 2024 144 Filing
Jun 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 28, 2024 8-K Current Report
May 17, 2024 144 Filing
May 8, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
Apr 11, 2024 DEF 14A Other definitive proxy statements
Apr 11, 2024 ARS Filing